Tumor Mutational Burden-High in Solid Malignant Tumors
Tumor mutational burden-high (TMB-H) solid malignant tumors represent a critical biomarker category in oncology, offering actionable insights into immunotherapy response prediction and patient stratification. Defined by an elevated number of somatic mutations per megabase (mut/Mb), TMB-H has emerged as a valuable indicator for the efficacy of immune checkpoint inhibitors, particularly in treatment-refractory malignancies. Defining Tumor